Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulgent Genetics, Inc.FLGT · Entity 2545 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulgent Genetics, Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,578 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 5,558 · Balance 24,578 F1: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.19 · Expires 2036-05-13 | Direct | 8,426 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 8,426 · Balance 8,426 F2: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date.
F2: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 18, 2026 22:51 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantStock Option (Right to Buy) · Derivative | 8,426 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001890563-26-000003 · ownership.xml · derivative · entry 2 Nohaile Michael · CIK 0001890563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,426 Underlying: Common Stock · 8,426 shares Expires 2036-05-13 F2 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. Read SEC document |
| May 14, 2026 Filed May 18, 2026 22:51 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 5,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001890563-26-000003 · ownership.xml · nonDerivative · entry 1 Nohaile Michael · CIK 0001890563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,578 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 14, 2026, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:32 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantStock Option (Right to Buy) · Derivative | 6,311 | $0.00 Strike: $20.04 | $0.00 |
DisclosureSEC source: 0000950170-25-074602 · ownership.xml · derivative · entry 2 Nohaile Michael · CIK 0001890563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,311 Underlying: Common Stock · 6,311 shares Expires 2035-05-14 F2 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 15, 2025, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:32 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 4,491 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074602 · ownership.xml · nonDerivative · entry 1 Nohaile Michael · CIK 0001890563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,020 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 15, 2025, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| May 16, 2024 Filed May 20, 2024 22:06 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062572 · ownership.xml · nonDerivative · entry 1 Nohaile Michael · CIK 0001890563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,529 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 16, 2024, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| May 18, 2023 Filed May 22, 2023 20:45 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantStock Option (Right to Buy) · Derivative | 3,380 | $0.00 Strike: $35.58 | $0.00 |
DisclosureSEC source: 0001209191-23-031485 · doc4.xml · derivative · entry 2 Nohaile Michael · CIK 0001890563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,380 Underlying: Common Stock · 3,380 shares Expires 2033-05-17 F2 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 18, 2023, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. Read SEC document |
| May 18, 2023 Filed May 22, 2023 20:45 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 2,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031485 · doc4.xml · nonDerivative · entry 1 Nohaile Michael · CIK 0001890563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,529 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after May 18, 2023, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| August 01, 2022 Filed Aug 10, 2022 22:08 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $59.54 | $0.00 |
DisclosureSEC source: 0001209191-22-045293 · doc4.xml · derivative · entry 2 Nohaile Michael · CIK 0001890563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-07-31 F2 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after August 1, 2022, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. Read SEC document |
| August 01, 2022 Filed Aug 10, 2022 22:08 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045293 · doc4.xml · nonDerivative · entry 1 Nohaile Michael · CIK 0001890563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after August 1, 2022, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.